Business Wire

MA-PRECISELY

8.12.2022 15:01:43 CET | Business Wire | Press release

Share
New Research Reveals Supply Chain Resiliency and Agility are Key Drivers for Process Automation

Precisely, the global leader in data integrity, in collaboration with SAPinsider, today announced the results of new global research that highlights the importance of process automation in building robust supply chains. Findings from the new benchmark report, Process Automation in Supply Chain, show that 51% of respondents cite resiliency as the top supply chain concern driving the need for process automation, with agility close behind at 46%. A backdrop of disruptive world events means businesses are increasingly battling against global supply chain disruption, as well as mounting pressures to keep pace with changing consumer preferences for digital, local, and sustainable goods – resulting in an urgent need for supply chain transformation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005434/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

51% of business leaders cite resiliency as top supply chain concern driving need for process automation (Graphic: Business Wire)

The research found that 89% of respondents believe process automation in the supply chain is either “important” or “very important” to attain digital transformation objectives. However, a major gap remains between where the industry needs to be and where it currently stands: Nearly three-fourths (72%) indicated that less than 50% of their supply chain processes are currently automated, with this dropping to just 25% for a further one-third of the respondents.

“With recent world events including the COVID-19 pandemic, the war in Ukraine, and impacts from climate change, it’s no surprise that supply chain resiliency is top of mind for businesses worldwide,” said Mark Vigoroso, Chief Content Officer at SAPinsider. “While adoption of technologies has been slow to-date, the need to create a resilient supply chain ecosystem has never been more apparent, and we’re seeing organizations increasingly turn to process automation as a way to build robust supply chain capabilities and help navigate the uncertainty in the market.”

“These new findings from SAPinsider highlight the importance of automation when it comes to complex, data intensive, SAP processes, such as for supply chain,” said John Reda, SVP – Product Management for Data Integration at Precisely. “The Precisely Automate Evolve platform, formerly Winshuttle Evolve, helps customers to gain agility and speed by simplifying and streamlining processes. The flexible, scalable nature of the platform helps create and maintain resilient supply chains - delivering increased efficiency, visibility and governance that improve results and reduce the risks inherent in today’s unpredictable business environment.”

The research additionally shows that the key objectives for deploying process automation have become more strategic over time, and include the realization of benefits such as:

  • End-to-end process visibility (82%)
  • Increased process efficiency (79%)
  • Defining and documenting standardization (77%)
  • Integrated processes across end-to-end supply chain (75%)
  • Building internal skillset (72%)

It also uncovers an increased appetite to explore more advanced automation technologies as businesses plan for 2023 and beyond -- with nearly half of all respondents (47%) stating intelligent automation, such as AI and machine learning, is a key capability they are considering implementing over the next 24 months.

“Ultimately, supply chain resilience relies upon a programmatic approach for improving end-to-end process visibility and risk monitoring. To be successful, supply chains must become both digital and autonomous to keep pace with disruptive global events and changing consumer expectations,” continued Reda. “It’s clear that process automation is critical, but the success of digitized processes and workflows will also rely upon the accuracy, consistency and context of the data feeding them. Supply chain transformation, fueled by data integrity, will be the key to confident decision-making during the uncertain times ahead.”

Read the full SAPinsider Benchmark Report Process Automation in Supply Chain here or for further insights on the role of process automation in building robust supply chains, view our on-demand webinar “Process Automation Trends in SAP Supply Chain for 2023” here.

About SAPinsider and Survey Methodology
SAPinsider comprises the largest and fastest growing SAP membership group worldwide, with more than 500,000 members across 205 countries. The Supply Chain Research Report, conducted in partnership with Precisely, surveyed SAP Insider members between July and September 2022 to gauge the use and future investment of process automation in supply chain. The survey was administered to 105 members of the SAPinsider Community and generated responses from across a wide range of geographies, industries, and company sizes.

About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005434/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye